HomeAI · summaries
Storia in 5 fonti
A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market
A Brazilian drugmaker filed to launch its own version of the blockbuster weight-loss and diabetes drug, taking aim at a market worth billions a year.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
riotimesonline.com
Brazil Wants to Put Ozempic-Style Drugs in Its Public Clinics
Brazil will pilot Ozempic-style weight-loss drugs in its public health system, a demand signal for Novo Nordisk and Eli Lilly once prices fall.
- ·
africa.businessinsider.com
South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs
A South African court has ordered pharmacy group iDexis to halt sales of semaglutide-based medicines in a legal victory for Novo Nordisk, maker of Ozempic and Wegovy
- ·
businessday.co.za
Novo Nordisk wins interim order barring SA rival from selling Ozempic copies
Interim order bars iDexis from selling weight-loss medicines containing semaglutide, the key ingredient in Ozempic and Wegovy
- ·
valor.globo.com
Nova caneta de semaglutida sintética produzida no Brasil é a Semavy, da Hypera Pharma
Caneta será voltada ao tratamento do diabetes tipo 2, e a farmacêutica ainda deve pedir autorização para uso na perda de peso
- ·
A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market
A Brazilian drugmaker filed to launch its own version of the blockbuster weight-loss and diabetes drug, taking aim at a market worth billions a year.
- ·
oglobo.globo.com
‘Ozempic nacional’: próxima caneta de semaglutida brasileira será chamada Semavy; conheça
Farmacêutica Hypera Pharma deu entrada no processo de definição do preço, uma das etapas regulatórias durante a análise de um novo medicamento no país